Price (delayed)
$108.31
Market cap
$10.8B
P/E Ratio
31.86
Dividend/share
N/A
EPS
$3.4
Enterprise value
$11.02B
Neurocrine Biosciences is a publicly traded biopharmaceutical company founded in 1992. The company is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological
There are no recent dividends present for NBIX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from and Sharadar.